Overview

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Status:
Terminated

Trial end date:
2020-07-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Anagrelide
Hydroxyurea